0001209191-23-044031.txt : 20230801 0001209191-23-044031.hdr.sgml : 20230801 20230801173254 ACCESSION NUMBER: 0001209191-23-044031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230801 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Andriole Michael T. CENTRAL INDEX KEY: 0001698751 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 231132970 MAIL ADDRESS: STREET 1: C/O ENDOCYTE, INC. STREET 2: 3000 KENT AVENUE, SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-01 0 0001117480 CHIMERIX INC CMRX 0001698751 Andriole Michael T. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 1 1 0 0 President and CEO 0 Common Stock 2023-08-01 4 A 0 25000 1.19 A 382015 D Stock Option (Right to Buy) 1.19 2023-08-01 4 A 0 150000 0.00 A 2033-07-31 Common Stock 150000 150000 D The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the RSUs will vest in equal annual installments over a four year period from 08/01/2023, so long as the Reporting Person continues to provide services to the Issuer. The shares subject to the nonstatutory stock option ("Option"), under Chimerix, Inc.'s 2013 Equity Incentive Plan, will vest over a period of four years so long as the Reporting Person continues to provide services to the Issuer, with 25% of the shares subject to the Option vesting on 08/01/2024 and the balance of shares vesting in 36 equal monthly installments over the remaining three years. /s/ Michael Alrutz, Attorney-in-Fact 2023-08-01